HERANTIS PHARMA

08/20/2026 20:59 EEST

This is a translated version of the ”Vaiheen 2 valmistelu etenee” report, published on 08/21/2026

Antti Siltanen, Analyst
+358 45 119 6869
antti.siltanen@inderes.fi

INDERES CORPORATE CUSTOMER

COMPANY REPORT

Phase 2 preparation is progressing

Herantis' H1 report did not offer any significant news. The company is preparing for the initiation of Phase 2 during H1'27, for which negotiations to secure the missing financing are underway. Costs for preparing the upcoming study exceeded our estimates in H1. As a result, we are moderately revising our earnings estimates for the coming years downwards. In line with our estimate revisions, we adjust our target price to EUR 2.0 (was EUR 2.2). As the share price has fallen, we believe that the risk/reward ratio has become attractive again, so we raise our recommendation to Accumulate (was Reduce).

Preparations for Phase 2 progressed as planned

Operationally, H1 was eventful. The Phase 1b biomarker results reported in January indicated HER-096's biological activity in the central nervous system. In February, the company received a 8.0 MEUR Horizon Europe grant. In May, the company agreed with Indivi on the use of a digital platform, which improves the ability to detect treatment effects, and in June, Herantis appointed a Chief Medical Officer and a contract research organization (CRO) The feedback from the FDA meeting was also positive and aligns Herantis' plans with the guidance of the U.S. Food and Drug Administration. The company's focus for H2 is on the investigational new drug application, manufacturing of the investigational drug, and partnership discussions. The first treatments are scheduled to begin in H1'27, with results expected in H1'29.

In terms of figures, H1 EBIT was -3.06 MEUR (H1'25: -2.96 MEUR) and fell short of our -1.9 MEUR estimate. We had expected costs to decrease from the comparison period, as Phase 1 patient visits ended in 2025 and patient visits for the upcoming study will not begin until next year. However, trial preparations, such as investigational drug production and production validation, raised costs upfront.

Current funding is sufficient for the first half of 2027

Cash and cash equivalents at the end of the period amounted to 3.51 MEUR after the 4.2 MEUR directed issue in February. According to the company, funds are sufficient until the end of H1'27, which suggests a decrease in costs from the H1 level. The remaining funding needed for the upcoming study is around 20 MEUR (with administrative costs ~30 MEUR), of which an 8.0 MEUR EU grant and a 10.8 MEUR commitment from the EIC Fund have been secured Our model includes a 12 MEUR share issue for this year, which, together with the EU grant and cash, we estimate would cover most of the financing need of the Phase 2 study. The financing situation still contains binary risk: non-dilutive solutions (partnership or grants) support the share price, while a potential large share issue could put pressure on it.

We make moderate adjustments to our cost estimates

We revise our EBIT estimate for the current year to -5.7 MEUR (was -4.1 MEUR) as a result of the high cash burn in the early part of the year. For 2027-28, we make only minor revisions, as we assume the cost increase in H1 was more timing-related than structural. The majority of the costs of the study occur in 2027-29 Our estimates for HER-096's launch timeline (2034/2035), probability of drug development success (~15%), and potential peak sales (~6 BEUR) remain unchanged.

Risk/reward ratio is attractive again

After the share price decline, we believe the stock's risk/reward ratio is attractive again. The baseline scenario in our DCF model gives the stock a value of EUR 2.0. We estimate the fair value range of the share to be EUR 0.7–5.1. Our assessment is based on DCF scenarios, where the positive scenario relies on favorable clinical results, non-dilutive research funding, and a rapid timeline. The negative scenario, on the other hand, represents mediocre results, a greater increase in the number of shares than our estimates, and a delay in commercialization.

Recommendation
Accumulate
(was Reduce)

Target price:
EUR 2.00
(was 2.20 EUR)

Share price:
EUR 1.53

Business risk

Valuation risk

	2025	2026e	2027e	2028e
Revenue	0.0	0.0	0.0	0.0
Growth-%	0 %	0 %	0 %	0 %
EBIT adj.	-6.4	-5.8	-6.8	-9.1
Net profit	-6.6	-6.0	-6.8	-9.1
EPS (adj.)	-0.27	-0.16	-0.18	-0.24
P/E (adj.)	neg.	neg.	neg.	neg.
P/B	neg.	7,0	34,2	neg.
Dividend yield-%	0.0 %	0.0 %	0.0 %	0.0 %
EV/EBIT (adj.)	neg.	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.	neg.
EV/Sales	>100	>100	>100	>100

Source: Inderes

Guidance (Unchanged)

Herantis does not provide any guidance.

Share price



Source: Millistream Market Data AB

Revenue and EBIT % (adj.)



Source: Inderes

EPS and dividend



Source: Inderes

Value drivers

- There is a great need for new drugs in Parkinson's disease that affect the progression of the disease.
- If the drug proves safe and effective, we feel that the achievable pricing is attractive.
- In terms of its operating mechanism, HER-096 could also be suitable for treating other neurodegenerative diseases such as Alzheimer's disease and ALS.
- The initial clinical study results are promising for the further development of HER-096.

Risk factors

- The risk of failure in development is very high due to the early development phase.
- The research program is still at an early stage, so Herantis needs substantial financing for drug development.
- A licensing agreement may not be reached or its terms may be unsatisfactory.
- Drugs that may enter the market before HER-096 could raise the threshold for market entry.
- The increase in the number of shares and the dilution of their value through share issues.

Valuation	2026e	2027e	2028e
Share price	1.60	1.60	1.60
Number of shares, millions	37.2	37.2	37.2
Market cap	60	60	60
EV	51	58	67
P/E (adj.)	neg.	neg.	neg.
P/E	neg.	neg.	neg.
P/FCF	9.3	neg.	neg.
P/B	7.0	34.2	neg.
P/S	>100	>100	>100
EV/Sales	>100	>100	>100
EV/EBITDA	neg.	neg.	neg.
EV/EBIT (adj.)	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %

Source: Inderes

Costs exceeded our expectations

EBIT

- The EBIT of -3.06 MEUR fell short of our estimate (1.9 MEUR) by some 1.2 MEUR.
- Phase 2 preparation costs incurred earlier than we expected (e.g., study design, drug candidate production, biomarker analysis, regulatory processes)
- However, the company's guidance on cash sufficiency (until the end of H1'27) suggests that costs will decrease significantly before patient recruitment begins in H1'27.

Balance sheet and cash flow

- Cash and cash equivalents were 3.51 MEUR at the end of the period; equity was negative at -0.80 MEUR, and the equity ratio was approximately -20%, with a balance sheet total of 4.04 MEUR.
- Cash flow from operating activities was -3.33 MEUR, investments -0.89 MEUR, and cash flow from financing was 4.21 MEUR due to the directed share issue in February.
- According to the company, cash resources are sufficient until the end of H1'27.

Herantis as an investment

- As a drug development company, Herantis does not yet have revenue.
- The company's value creation is based on advancing research. If the results are good, the probability of commercializing the drug increases. In the commercial phase, we expect Herantis to receive license payments from a larger pharmaceutical partner, who will handle the global sales and marketing of the drug.
- Poor research results most likely mean a permanent loss of capital for the investor.
- HER-096, an investigational drug being developed for Parkinson's disease and potentially other neurodegenerative diseases, has cleared clinical Phase 1.
- Based on the Phase 1 results, the drug candidate behaves as expected in the body, reaches its target in the central nervous system at a sufficient concentration, and is safe and well-tolerated in short-term administration in a small group of subjects.
- Next on the agenda is a Phase 2 study lasting around 3 years, which will investigate the tolerability, safety, and preliminary efficacy of longer-term (15 months) dosing.
- If the results are positive, the company can proceed to a pivotal Phase 3 study for marketing authorization, which is significantly larger in duration and patient numbers than Phase 2.

Estimates	H1'25	H1'26	H1'26e	H1'26e	Consensus		Difference (%)	2026e
MEUR / EUR	Comparison	Actualized	Inderes	Consensus	Low	High	Act. vs. inderes	Inderes
Revenue	0.0	0.0	0.0					0.0
EBIT	-2.96	-3.06	-1.85				-65%	-5.66
EPS (reported)	-0.13	-0.12	-0.06				-103%	-0.16

Source: Inderes

We revise our cost estimates moderately

Estimate revisions

- We revise our current year estimates downward due to higher-than-expected H1 expenses.
- The company's comments on cash sufficiency suggest a decreasing cost level and/or the utilization of EU grants before patient recruitment begins in H1'27.
- There are no significant changes in our cost estimates for the coming years, as we assume that the increase in H1'26 costs is due more to timing factors than structurally higher cost increases

Financing

- According to Herantis, the direct costs of the Phase 2 study are around 20 MEUR, in addition to which, administrative costs will increase the total cost of completing Phase 2 to approximately 30 MEUR (H1'26 webcast).
- Herantis has received an EU grant of 8.0 MEUR, and the company has a remaining EIC commitment for a 10.8 MEUR equity investment. The EIC will participate in the capital injection with a maximum of 1/3.
- We have modeled a directed issue of 12 MEUR for this year at a price of EUR 1.5 per share, which would fully or largely cover the financing needs until the end of Phase 2.

Long-term estimates

- The Phase 2 study is a high-quality, randomized, double-blind study. It provides high-quality data.
- There are about 100 patients and the duration of the study is 15 months. These factors limit statistical power and the demonstration of efficacy. In other words, obtaining highly reliable data requires larger patient populations, and the definitive demonstration of efficacy and safety requires longer-term experimental treatment and follow-up.
- If the Phase 2 results are sufficiently good, Herantis will conduct a pivotal Phase 3 study for marketing authorization. A large and long-lasting study requires significant funding, which, in our estimates, will primarily be secured through a licensing agreement.
- If the study program progresses favorably, we consider obtaining marketing authorization possible in 2034 in the US and the following year elsewhere in the world.
- In the absence of efficacy and long-term safety data, the approval of HER-096 as a drug is still relatively unlikely We estimate the probability to be around 15% based on historical averages, which we have discussed here.
- We estimate the potential peak sales to be around 6 BEUR. The calculation can be found on page 7.
- More on the estimates and their background can be found in our extensive report.

Estimate revisions	2026e	2026e	Change	2027e	2027e	Change	2028e	2028e	Change
MEUR / EUR	Old	New	%	Old	New	%	Old	New	%
Revenue	0.0	0.0	0%	0.0	0.0	0%	0.0	0.0	0%
EBITDA	-4.1	-5.7	-38%	-6.1	-6.6	-7%	-8.4	-8.6	-3%
EBIT	-4.1	-5.7	-38%	-6.1	-6.6	-7%	-8.4	-8.6	-3%
PTP	-4.3	-5.9	-37%	-6.1	-6.6	-7%	-8.4	-8.6	-3%
EPS (excl. NRIs)	-0.12	-0.16	-28%	-0.18	-0.18	0%	-0.24	-0.23	4%
DPS	0.00	0.00		0.00	0.00		0.00	0.00	

Source: Inderes

Herantis Pharma, Webcast, Q2'26

Valuation attractive again after share price drop

The valuation is based on risk-adjusted estimates

Herantis is a very high-risk investment because the company's business depends virtually entirely on developing a single drug candidate. Weak study results regarding safety or efficacy could destroy the invested capital, even entirely. Capital destruction is a relatively likely outcome based on the probabilities of successful drug development. In a positive development, Herantis succeeds in commercialization first in Parkinson's disease and later in other neurodegenerative diseases, which could lead to a multi-fold increase in the share price from current levels. Regarding other indications, the company currently has no clinical program, so our model relies purely on Parkinson's disease at this time.

Our estimate for the probability of HER-096 reaching the market is around 15%. Potentially good results in future studies increase the probability. Our assessment is mainly based on historical probabilities, which we have discussed in this article. Our estimate for post-marketing authorization revenue relies on our assessed patient numbers, the potential sales price of the drug, royalty payments, and other variables, which are described in more detail in our extensive report and the table on the following page.

DCF baseline scenario value EUR 2.0

Our valuation is based on risk-weighted estimates that consider the binary risk associated with the probability of success in drug development. In the absence of revenue, our estimate is based on a DCF calculation (discounted cash flow model) that models the present value of cash flows far in the future (in the 2030s). Our updated view (was EUR 2.2) based on estimate revisions.

We estimate the valuation through three DCF scenarios, which are presented in the chart below. Based on the scenarios, we determine the fair value of the share to be in a wide range of EUR 0.7-5.1. We note that the scenarios do not represent our view of the best and worst possible path for the business but are intended to provide investors with a perspective on the sensitivity of the valuation and various development paths that we believe are realistic.

Thus, the DCF model is highly sensitive to the assumptions used. Investors should look at DCF in this type of share more as indicative than a precise indicator of share value. The weighted average cost of capital (WACC) in our DCF model is 12%, which is a typical level for the industry. From a business perspective, WACC is raised by uncertainty of the timing of revenue, the drug's sales price, the achievable revenue, and the terms of possible cooperation agreements, including the royalty percentage. On the other hand, the industry's defensive nature and the strong cash flows resulting from market entry limit the risk level.

A positive option for investors is a scenario where a larger pharmaceutical company acquires Herantis or licenses the rights to the HER-096 asset at a significant premium to the current valuation. We consider the probability of an acquisition to be low at this stage and do not see it having a significant impact on the expected return. In our opinion, a licensing agreement is a significantly more probable option, which is reflected in the optimistic scenario of our fair value range. The table below provides investors with examples of industry agreements from recent years for reference.

DCF valuation ranges

	Optimistic	Pessimistic
Probability of success	30%	10%
Dilution of share capital (current estimate ~30%)	0%	50%
Duration of the study program	Based on estimates	Commercialization delay of 1 year
DCF value of the share	**5.1**	**0.7**

Source: Inderes

The optimistic scenario assumes a successful Phase 2 study that supports the implementation of the pivotal phase. The study is fully funded on a non-dilutive basis and will be completed in line with our schedule estimate.

The pessimistic scenario is based on clinically uncertain results regarding efficacy and safety, meaning the uncertainty of success remains high. The study program is delayed from the plan, and its financing will increase the number of shares more than we estimate.

Examples of industry agreements 2025–26

Year	Company	Indication	Advance payment	Total value
2025	Arrowhead pharmaceuticals	PD	200	2200
2025	Abl bio	ND	49	2732
2025	Bioarctic	ND	30	802
2026	Scineuro pharmaceuticals	AD	165	1665
2026	Frontier biotechnologies	ND	40	1003
2026	Alzecure pharma	AD	10	1000
2026	Bioarctic	ND	30	800
2026	Alzecure pharma	AD, PD	7	2212

Source: Inderes

PD = Parkinson's disease; AD = Alzheimer's disease; ND = neurodegeneration

Estimates

	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041
HER-096, US												
Prevalence of Parkinson's disease	1,201,025	1,225,045	1,250,000	1,275,000	1,300,000	1,326,000	1,353,000	1,380,000	1,407,000	1,435,000	1,464,000	1,493,000
Eligible patients, %	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%
Potential patients	600,512	612,523	625,000	637,000	650,000	663,000	676,000	690,000	704,000	718,000	732,000	747,000
Market share, %	0%	0%	0%	0%	2%	8%	16%	20%	20%	20%	10%	0%
Patients that stop using the drug, %	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%
Price/year/patient, MEUR	0.02	0.02	0.02	0.02	0.02	0.02	0.03	0.03	0.03	0.03	0.03	0.03
Royalty share, %	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
Revenue	**0**	**0**	**0**	**0**	**34**	**176**	**381**	**496**	**516**	**537**	**286**	**0**
Probability of success	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
Revenue, risk-adjusted	**0**	**0**	**0**	**0**	**5**	**26**	**56**	**72**	**75**	**78**	**42**	**0**
HER-096, other markets												
Prevalence of Parkinson's disease	1,791,078	1,826,900	1,863,000	1,901,000	1,939,000	1,977,000	2,017,000	2,057,000	2,099,000	2,141,000	2,183,000	2,227,000
Eligible patients, %	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%
Potential patients	895,539	913,450	932,000	950,000	969,000	989,000	1,009,000	1,029,000	1,049,000	1,070,000	1,092,000	1,113,000
Market share, %	0%	0%	0%	0%	0%	2%	8%	16%	20%	20%	10%	0%
Patients that stop using the drug, %	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%
Price/year/patient, MEUR	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Royalty share, %	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
Revenue	**0**	**0**	**0**	**0**	**0**	**26**	**137**	**294**	**385**	**400**	**214**	**0**
Probability of success	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
Revenue, risk-adjusted	**0**	**0**	**0**	**0**	**0**	**4**	**20**	**43**	**56**	**58**	**31**	**0**
Top sale, total			**0**	**0**	**226**	**1350**	**3453**	**5266**	**6004**	**6247**	**3333**	**0**
US	0	0	0	0	226	1175	2542	3306	3440	3579	1909	0
Other countries	0	0	0	0	0	175	911	1959	2565	2668	1424	0
Risk-adjusted revenue, total	**0.0**	**0.0**	**0**	**0**	**5**	**30**	**76**	**115**	**131**	**137**	**73**	**0**
US	0.0	0.0	0	0	5	26	56	72	75	78	42	0
Other countries	0.0	0.0	0	0	0	4	20	43	56	58	31	0

Valuation table

Valuation	2021	2022	2023	2024	2025	2026e	2027e	2028e	2029e
Share price	2.40	1.65	1.58	1.52	2.04	**1.60**	**1.60**	**1.60**	**1.60**
Number of shares, millions	11.1	16.9	20.2	20.2	24.1	**37.2**	**37.2**	**37.2**	**37.2**
Market cap	27	28	32	31	49	**60**	**60**	**60**	**60**
EV	26	26	25	29	47	**51**	**58**	**67**	**76**
P/E (adj.)	neg.	neg.	>100	neg.	neg.	**neg.**	**neg.**	**neg.**	**neg.**
P/E	neg.	neg.	>100	neg.	neg.	**neg.**	**neg.**	**neg.**	**neg.**
P/FCF	neg.	neg.	85.9	neg.	96.0	**9.1**	**neg.**	**neg.**	**neg.**
P/B	neg.	neg.	6.8	neg.	neg.	**6.9**	**28.7**	**neg.**	**neg.**
P/S	>100	>100	>100	>100	>100	**>100**	**>100**	**>100**	**>100**
EV/Sales	>100	>100	>100	>100	>100	**>100**	**>100**	**>100**	**>100**
EV/EBITDA	neg.	neg.	>100	neg.	neg.	**neg.**	**neg.**	**neg.**	**neg.**
EV/EBIT (adj.)	neg.	neg.	>100	neg.	neg.	**neg.**	**neg.**	**neg.**	**neg.**
Payout ratio (%)	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	**0.0 %**	**0.0 %**	**0.0 %**	**0.0 %**
Dividend yield-%	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	**0.0 %**	**0.0 %**	**0.0 %**	**0.0 %**

Source: Inderes

The market cap and enterprise value in the table consider the expected change in the number of shares and net debt for the forecast years.

Income statement

Income statement	H1'24	H2'24	2024	H1'25	H2'25	2025	H1'26e	H2'26e	2026e	2027e	2028e	2029e
Revenue	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
EBITDA	**-2.8**	**-2.3**	**-5.0**	**-3.0**	**-3.4**	**-6.4**	**-3.1**	**-2.6**	**-5.8**	**-6.8**	**-9.1**	**-8.4**
Depreciation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (excl. NRI)	**-2.8**	**-2.3**	**-5.0**	**-3.0**	**-3.4**	**-6.4**	**-3.1**	**-2.6**	**-5.8**	**-6.8**	**-9.1**	**-8.4**
EBIT	**-2.8**	**-2.3**	**-5.0**	**-3.0**	**-3.4**	**-6.4**	**-3.1**	**-2.6**	**-5.8**	**-6.8**	**-9.1**	**-8.4**
Share of profits in assoc. compan.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net financial items	0.0	0.0	0.0	-0.3	0.0	-0.2	-0.2	0.0	-0.2	0.0	0.0	0.0
PTP	**-2.8**	**-2.3**	**-5.0**	**-3.2**	**-3.4**	**-6.6**	**-3.3**	**-2.6**	**-6.0**	**-6.8**	**-9.1**	**-8.4**
Taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net earnings	**-2.8**	**-2.3**	**-5.0**	**-3.2**	**-3.4**	**-6.6**	**-3.3**	**-2.6**	**-6.0**	**-6.8**	**-9.1**	**-8.4**
Net earnings	**-2.8**	**-2.3**	**-5.0**	**-3.2**	**-3.4**	**-6.6**	**-3.3**	**-2.6**	**-6.0**	**-6.8**	**-9.1**	**-8.4**
EPS (adj.)	**-0.14**	**-0.11**	**-0.25**	**-0.13**	**-0.14**	**-0.27**	**-0.09**	**-0.07**	**-0.16**	**-0.18**	**-0.24**	**-0.23**
EPS (rep.)	**-0.14**	**-0.11**	**-0.25**	**-0.13**	**-0.14**	**-0.27**	**-0.09**	**-0.07**	**-0.16**	**-0.18**	**-0.24**	**-0.23**

Source: Inderes

Full-year earnings per share are calculated using the number of shares at year-end.

Balance sheet

Assets	2024	2025	2026e	2027e	2028e
Non-current assets	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
Goodwill	0.0	0.0	0.0	0.0	0.0
Intangible assets	0.0	0.0	0.0	0.0	0.0
Tangible assets	0.0	0.0	0.0	0.0	0.0
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	0.0	0.0	0.0	0.0	0.0
Other non-current assets	0.0	0.0	0.0	0.0	0.0
Deferred tax assets	0.0	0.0	0.0	0.0	0.0
Current assets	**2.6**	**2.7**	**8.5**	**1.7**	**0.3**
Inventories	0.0	0.0	0.0	0.0	0.0
Other current assets	0.0	0.0	0.0	0.0	0.0
Receivables	0.4	0.1	0.3	0.3	0.3
Cash and equivalents	2.1	2.6	8.4	1.8	0.0
Balance sheet total	**2.6**	**2.7**	**8.5**	**1.7**	**0.3**

Source: Inderes

Liabilities & equity	2024	2025	2026e	2027e	2028e
Equity	**-0.3**	**-1.7**	**8.6**	**1.7**	**-7.3**
Share capital	0.1	0.1	0.1	0.1	0.1
Retained earnings	-80.1	-86.7	-92.7	-99.5	-108.6
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	0.0	0.0	0.0	0.0	0.0
Other equity	79.7	84.9	101	101	101
Minorities	0.0	0.0	0.0	0.0	0.0
Non-current liabilities	**2.2**	**3.4**	**0.0**	**0.0**	**6.1**
Deferred tax liabilities	0.0	0.0	0.0	0.0	0.0
Provisions	0.0	0.0	0.0	0.0	0.0
Interest bearing debt	0.0	0.0	0.0	0.0	6.1
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	2.2	3.4	0.0	0.0	0.0
Current liabilities	**0.6**	**0.9**	**0.0**	**0.0**	**1.5**
Interest bearing debt	0.0	0.0	0.0	0.0	1.5
Payables	0.6	0.9	0.0	0.0	0.0
Other current liabilities	0.0	0.0	0.0	0.0	0.0
Balance sheet total	**2.5**	**2.7**	**8.5**	**1.7**	**0.3**

DCF-calculation

DCF model	2025	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	2038e	2039e	2040e	2041e	TERM
Revenue growth-%	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	NA	497.8 %	155.8 %	52.5 %	14.0 %	4.0 %	-46.6 %	-100.0 %	0.0 %
EBIT-%	-63990.0 %	-56630.0 %	-65701.6 %	-90932.7 %	-84234.1 %	-97715.6 %	########	########	########	-69.6 %	70.9 %	88.3 %	92.1 %	92.9 %	93.0 %	93.4 %	93.4 %	93.4 %
EBIT (operating profit)	**-6.4**	**-5.8**	**-6.8**	**-9.1**	**-8.4**	**-9.8**	**-11.6**	**-12.0**	**-10.9**	**-3.4**	**20.9**	**66.7**	**106**	**122**	**127**	**68.1**	**0.0**	
+ Depreciation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Paid taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-12.0	-19.1	-22.0	-22.9	-12.3	0.0	
- Tax. financial expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
+ Tax. financial income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Change in working capital	0.6	-1.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Operating cash flow	**-5.8**	**-6.8**	**-6.8**	**-9.1**	**-8.4**	**-9.8**	**-11.6**	**-11.8**	**-10.9**	**-3.4**	**20.9**	**54.7**	**87.0**	**100**	**104**	**55.8**	**0.0**	
+ Change in other long-term liabilities	1.3	-3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free operating cash flow	**-4.5**	**-10.3**	**-6.8**	**-9.1**	**-8.4**	**-9.8**	**-11.6**	**-11.8**	**-10.9**	**-3.4**	**20.9**	**54.7**	**87.0**	**100**	**104**	**55.8**	**0.0**	
+/- Other	5.0	16.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	0.5	6.4	-6.8	-9.1	-8.4	-9.8	-11.6	-11.8	-10.9	-3.4	20.9	54.7	87.0	100	104	55.8	0.0	0.0
Discounted FCFF		**6.2**	**-5.8**	**-7.0**	**-5.8**	**-6.0**	**-6.4**	**-5.7**	**-4.8**	**-1.3**	**7.3**	**17.0**	**24.1**	**24.8**	**23.0**	**11.0**	**0.0**	**0.0**
Sum of FCFF present value		70.6	64.5	70.3	77.3	83.0	89.0	95.4	101	106	107	99.9	82.9	58.8	34.1	11.0	0.0	0.0

Enterprise value DCF	**70.6**
- Interest bearing debt	0.0
+ Cash and cash equivalents	2.6
+ Associated companies	0.0
-Minorities	0.0
-Dividend/capital return	0.0
Equity value DCF	**73.2**
Equity value DCF per share	**2.0**

WACC	
Tax-% (WACC)	20.0 %
Target debt ratio (D/(D+E)	0.0 %
Cost of debt	8.0 %
Equity Beta	1.78
Market risk premium	4.75 %
Liquidity premium	1.00 %
Risk free interest rate	2.5 %
Cost of equity	**12.0 %**
Weighted average cost of capital (WACC)	**12.0 %**

Source: Inderes



Summary

Income statement	2023	2024	2025	2026e	2027e
Revenue	0.0	0.0	0.0	**0.0**	**0.0**
EBITDA	0.2	-5.0	-6.4	**-5.8**	**-6.8**
EBIT	0.2	-5.0	-6.4	**-5.8**	**-6.8**
PTP	0.3	-5.0	-6.6	**-6.0**	**-6.8**
Net Income	0.3	-5.0	-6.6	**-6.0**	**-6.8**
Extraordinary items	0.0	0.0	0.0	**0.0**	**0.0**

Balance sheet	2023	2024	2025	2026e	2027e
Balance sheet total	6.7	2.6	2.7	**8.5**	**1.7**
Equity capital	4.7	-0.3	-1.7	**8.5**	**1.7**
Goodwill	0.0	0.0	0.0	**0.0**	**0.0**
Net debt	-6.4	-2.1	-2.6	**-8.3**	**-1.5**

Cash flow	2023	2024	2025	2026e	2027e
EBITDA	0.2	-5.0	-6.4	**-5.8**	**-6.8**
Change in working capital	0.2	-1.5	0.6	**-1.1**	**0.0**
Operating cash flow	0.4	-6.6	-5.8	**-6.8**	**-6.8**
CAPEX	0.0	0.0	0.0	**0.0**	**0.0**
Free cash flow	0.4	-4.4	0.5	**6.4**	**-6.8**

Per share data	2023	2024	2025	2026e	2027e
EPS (reported)	0.01	-0.25	-0.27	**-0.16**	**-0.18**
EPS (adj.)	0.01	-0.25	-0.27	**-0.16**	**-0.18**
OCF / share	0.02	-0.33	-0.24	**-0.18**	**-0.18**
OFCF / share	0.02	-0.22	0.02	**0.17**	**-0.18**
Book value / share	0.23	-0.01	-0.07	**0.23**	**0.05**
Dividend / share	0.00	0.00	0.00	**0.00**	**0.00**

Source: Inderes

The market cap and enterprise value in the table consider the expected change in the number of shares and net debt for the forecast years. Per-share figures are calculated using the number of shares at year-end.

Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy	The 12-month risk-adjusted expected shareholder return of the share is very attractive
Accumulate	The 12-month risk-adjusted expected shareholder return of the share is attractive
Reduce	The 12-month risk-adjusted expected shareholder return of the share is weak
Sell	The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

Recommendation history (>12 mo)

Date	Recommendation	Target	Share price
6/19/2024	Accumulate	2.20 €	1.63 €
8/23/2024	Accumulate	2.20 €	1.60 €
3/7/2025	Accumulate	1.90 €	1.33 €
8/22/2025	Accumulate	2.10 €	1.79 €
10/9/2025	Reduce	2.50 €	2.78 €
11/20/2025	Accumulate	2.50 €	2.00 €
12/22/2025	Accumulate	2.50 €	1.98 €
1/9/2026	Reduce	2.50 €	2.55 €
3/6/2026	Accumulate	2.40 €	2.03 €
6/3/2026	Reduce	2.20 €	2.27 €
21/08/826	Accumulate	2.00 €	1.53 €

CONNECTING INVESTORS AND COMPANIES.

Inderes connects investors and listed companies.

We serve over 400 Nordic listed companies that want to better serve investors. The Inderes community is home to over 70,000 active investors.

We provide listed companies with solutions that enable seamless and effective investor relations. The Inderes service is built on four cornerstones for high-quality investor relations: Equity Research, Events, IR Software, and Annual General Meetings (AGM).

Inderes operates in Finland, Sweden, Norway, and Denmark and is listed on the Nasdaq First North Growth Market.

Inderes was created by investors, for investors.

Inderes Ab
Vattugatan 17, 5tr
Stockholm
+46 8 411 43 80

inderes.se

Inderes Oyj
Porkkalankatu 5
00180 Helsinki
+358 10 219 4690

inderes.fi

inderes.